Neurocrine Biosciences (NBIX) Misses Q4 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail
Get Alerts NBIX Hot Sheet
Price: $142.70 -0.41%
Revenue Growth %: +30.8%
Financial Fact:
Deferred gain on real estate: 853K
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Revenue Growth %: +30.8%
Financial Fact:
Deferred gain on real estate: 853K
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Neurocrine Biosciences (NASDAQ: NBIX) reported Q4 EPS of $0.07, $0.11 worse than the analyst estimate of $0.18. Revenue for the quarter came in at $94.52 million versus the consensus estimate of $87.77 million.
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- SLM (SLM) Misses Q3 EPS by 36c; lowers guidance
- Pfizer's 25-valent pneumococcal vaccine shows Phase 2 results
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
